TickerTalks
Browse all tickers →
TickerTalks›$TTRX
TTTTRX

Turn Therapeutics Inc.

$TTRX·$272M·Biotechnology·Healthcare
$9.12+1.0%YTD+117.7%1Y+30.3%
Mentions · last 7 days
2026-07-11: 1 posts2026-07-12: 2 posts2026-07-13: 7 posts2026-07-14: 2 posts2026-07-15: 0 posts2026-07-16: 3 posts2026-07-17: 0 posts15-4%
Price updated 7h ago·X counts updated 6h ago
TTTTRX
$TTRXTurn Therapeutics Inc.
$9.12+1.00%15 posts-4%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $TTRX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventAcceleratingAI verdict · as of 2026-07-17

The move is getting stronger, with heavier trading behind it.

TTRX up 116% YTD on 48% above the 50-day — a fresh biotech name with specific pipeline momentum.

TTRX is a specific clinical-stage biotech whose tape has moved decisively — up 116% year-to-date and 48% above the 50-day at a coverage-gap 52-week range. The specific pipeline framing is the whole thesis.

Where the picture reads:

  • The economics are pre-revenue by design: zero gross margin and -50% ROIC — meaning the equity is a pure claim on the specific pipeline milestones arriving.
  • The tape confirms specific institutional flow: sitting 48% above the 50-day with 200-day and 52-week range coverage gaps — meaning specific fresh-listing tape mechanics.
  • The specific volume signal is roughly at average: meaning the specific move has been made on real institutional flow, not just retail momentum.
  • The sentiment corpus is empty for this ticker — meaning there's no discretionary read from social flow, and the equity signal has to come entirely from operational and pipeline disclosure.

Sept 2 earnings is the trigger. A number confirming specific pipeline milestone timing plus cash-runway commentary extends the leg; a specific timeline slippage or safety-signal disclosure is the specific setup that would compress the acceleration.

What to watch: The Sept 2 print — pipeline milestone timing, cash-runway update, and any specific data-readout commentary. A specific pipeline calendar extends the leg; a slippage or safety-signal disclosure compresses the acceleration.

On the calendar: 2026-09-02 — Q2 earnings

Read the AI verdict + X sentiment for $TTRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops topical drugs for skin, nail, and eye conditions using proprietary nanoparticle delivery technology to enhance drug penetration.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $TTRX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $TTRX

Neutral — Develops topical drugs for skin, nail, and eye conditions using proprietary nanoparticle delivery technology to enhance drug penetration; limited exposure means the GLP-1 pipeline bifurcation and ADA oral formulation competition is not a near-term catalyst or headwind.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-40.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-49.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-117%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 11, 2026$-0.03$-0.02-50.0%
Q4 2025Mar 31, 2026$-0.09$-0.05-76.5%
Q3 2025Nov 13, 2025$-0.07——
Next earningsWed, Sep 2·consensus EPS $-0.02

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.03$-1.6M
Q4 FY25$0———$0.01$-1.2M
Q3 FY25$0———$-0.07$-589K
Q2 FY25$0———$-0.09$-500K

Forward consensus

5-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$200K$200K – $200K-$0.10-$0.10 – -$0.101
FY27$2.5M$2.5M – $2.5M-$0.15-$0.15 – -$0.151
FY28$0$0 – $0-$0.17-$0.17 – -$0.170
FY29$0$0 – $0-$0.18-$0.18 – -$0.180
FY30$72.5M$72.5M – $72.5M$0.69$0.69 – $0.691

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+46.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 10.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.105-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJul 78-K — Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics Inc. issued a press release and an updated investor presentation on July 7, 2026 under Regulation FD. Both documents are furnished as exhibits (not filed) and their specific content is not reproduced in the filing body excerpt. Reg FD update — topic and substance are in the attached exhibits; investors should review the press release and investor presentation for any material clinical or pipeline news.

8-KPress release / Reg FDJun 38-K — Item 7.01: Press release / Reg FD
AI summary

TTRX (TTRX) disclosed its addition to Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 under 8-K Item 8.01 (other events). Index inclusions are significant because they trigger automatic buying from passive index funds and ETFs that track the benchmark, often resulting in increased share price and trading volume. Index providers typically announce additions in advance of the effective rebalancing date, giving institutions time to adjust their holdings. The event increases TTRX's institutional ownership base and enhances its market visibility and liquidity profile.

8-KPress release / Reg FDJun 18-K — Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics (TTRX) issued a press release on June 1, 2026; full content in Exhibit 99.1 with no details in the filing body. Body unavailable — exhibit-only press release.

8-KPress release / Reg FDMay 278-K — Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics Inc. filed an 8-K under Item 7.01 (Regulation FD) on May 27, 2026, attaching a press release as Exhibit 99.1. The 8-K body contains only boilerplate Reg FD disclosure language; the actual content of the press release — the subject, topic, or any material information — is in Exhibit 99.1 and is not available in the excerpt. Body unavailable — Reg FD exhibit text not included in the body excerpt.

8-KPress release / Reg FDMay 198-K — Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics Inc. (TTRX) filed an 8-K on May 19, 2026 under Item 7.01 (Regulation FD Disclosure). Turn Therapeutics is a Westlake Village, California-based biopharmaceutical company listed on Nasdaq. Reg FD disclosures for a clinical-stage biotech typically accompany investor presentations at conferences or pipeline data updates.

8-KPress release / Reg FDMay 188-K — Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics Inc. (TTRX) issued a press release on May 18, 2026 under Item 7.01 Regulation FD Disclosure, furnished as Exhibit 99.1. The content of the press release is not visible in the available excerpt. Materiality cannot be assessed from the excerpt alone; this is a standard Reg FD filing by a clinical-stage biotech.

8-KMaterial agreementMar 248-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 3.02: Unregistered equity sale · Item 7.01: Press release / Reg FD
AI summary

Turn Therapeutics Inc. (TTRX) entered into a Loan Agreement providing up to $25.0 million in term loans in three tranches: Tranche 1 ($7.0M at closing), Tranche 2 (up to $8.0M available September 2026-March 2027, subject to clinical and financing milestones), and Discretionary Tranche 3 (up to $10.0M, January 2027-June 2028, requiring mutual agreement and milestone achievement). Loans bear interest at the greater of prime + 5.50% or 12.25% per annum, are secured by all company assets including IP, and mature October 1, 2029. This is a material new debt facility providing critical runway capital for a clinical-stage biotech, with milestone-gated tranches that limit commitment while preserving development flexibility.

8-KPress release / Reg FDFeb 178-K — Item 7.01: Press release / Reg FD
+ 12 other (2 earnings 8-Ks · 2 EFFECTs · 2 POS AMs · 1 C-TR) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readoutmarketbeat.com·7d agoWhy Is Turn Therapeutics Stock Trading Higher Today?benzinga.com·11d agoTurn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitisbusinesswire.com·11d agoTurn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitisbusinesswire.com·12d agoTurn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitisbusinesswire.com·47d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$RXRX
Voices on X · last 7 days

No standout posts about $TTRX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport